Chulalongkorn University

Running trials

• Not yet recruiting

  Trial Without Borders IMPLEMENT-CKD: IMPLEMENTation of Evidence-Based SGLT2i to Reduce Global Burden of Cardiovascular and Chronic Kidney Disease

  NCT07854808· Source

• Recruiting

  A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

  NCT07298421· Phase 3· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

  NCT07158242· Phase 3· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Source

• Active, not recruiting

  Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

  NCT07439055· Phase 2/3· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Source

• Recruiting

  The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

  NCT06030843· Phase 2/3· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· Source

• Active, not recruiting

  A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

  NCT06421636· Phase 2· Source

• Recruiting

  Thailand ATTR-CM Registry

  NCT06338696· Source

• Recruiting

  COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation (COOL-AF) Phase 2

  NCT06396299· Source

• Active, not recruiting

  A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

  NCT06356311· Phase 3· Source

• Recruiting

  Drospirenone Only Pills and Cervical Mucus Changes: A Pre- and Post-Bariatric Surgery Study

  NCT06345586· Source

• Recruiting

  Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study

  NCT06345560· Phase 1/2· Source

• Recruiting

  Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  NCT06136624· Phase 3· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Source

• Active, not recruiting

  A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

  NCT06097364· Phase 3· Source

• Active, not recruiting

  A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

  NCT05722015· Phase 3· Source

• Active, not recruiting

  Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

  NCT05555732· Phase 3· Source

• Active, not recruiting

  A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

  NCT05239728· Phase 3· Source

• Active, not recruiting

  Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

  NCT05215340· Phase 3· Source

• Active, not recruiting

  Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

  NCT04380636· Phase 3· Source

• Active, not recruiting

  Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals

  NCT03042754· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Obesity2 recruiting
• Amyloidosis1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Heart failure1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Home-Based Circuit Training in Adults With Obesity

  NCT07619612· Source

• Completed

  A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

  NCT06465186· Phase 2· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Source

• Completed

  A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

  NCT05342636· Phase 1/2· Source

• Completed

  Self-compassion to Reduce Diabetes Distress in Persons With Type 1 Diabetes

  NCT05070949· Source

• Completed

  Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

  NCT04725188· Phase 2· Source

• Completed

  Efficacy, Safety and Pharmacokinetics of DTG With RIF

  NCT03731559· Phase 2· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Phase 2· Source

• Completed

  Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis

  NCT02755610· Source

• Completed

  A Prospective Cohort of Children With HIV Infection

  NCT00476606· Source

Trial sites

• Chest Division, Faculty of Medicine, Chulalongkorn University1 trial
• Chulalongkorn University14 trials
• Chulalongkorn University (Site 1301)1 trial
• Chulalongkorn University (Site 1530)1 trial
• Chulalongkorn University (Site 2104)1 trial
• Chulalongkorn University (Site 2403)1 trial
• Chulalongkorn University (Site 2800)1 trial
• Chulalongkorn University (Site 3003)1 trial
• Chulalongkorn University (Site 3005)1 trial
• Chulalongkorn University (Site 3403)1 trial
• Chulalongkorn University (Site 3702)1 trial
• Chulalongkorn University (Site 4301)1 trial
• Chulalongkorn University (Site 5001)1 trial
• Faculty of Medicine at Chulalongkorn University1 trial
• Faculty of Medicine Chulalongkorn University6 trials
• Faculty of Sports Science, Chulalongkorn University1 trial
• Pediatric infectious diseases section, Chulalongkorn University1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• HIV94 works · 2 trials
• Parkinson disease55 works · 0 trials
• Chronic kidney disease44 works · 2 trials
• Tuberculosis39 works · 1 trials
• Depression30 works · 0 trials
• Fatty liver disease (MASLD/MASH)26 works · 2 trials
• Cervical cancer23 works · 1 trials
• Glaucoma15 works · 0 trials
• Thalassaemia11 works · 1 trials
• Long COVID and ME/CFS10 works · 0 trials
• Familial hypercholesterolaemia9 works · 0 trials
• Haemophilia8 works · 1 trials